Immune signaling & clinical research
Thymosin Alpha-1 research.
Put immune claims into context.
Immune health is complicated, and a long research history can still leave important questions. Understand Thymosin Alpha-1, compare disease-specific studies with wellness claims, and discuss your concerns with an appropriate clinician.
Educational research topic · No Thymosin Alpha-1 treatment is offered on this page.
Questions worth exploring
Clear prices. A clearer next step.
Explore the research. Understand the price context.
The research-market figure below is educational context. Neither a free account nor optional membership purchases access to this compound.
Published research-market starting price · not a treatment offer
Thymosin Alpha-1 · research market context
Listed from $81per research vial · quantity varies by selected 5 mg or 10 mg variant
Lowest displayed catalog price across the 5 mg and 10 mg variants. The exact price-to-quantity mapping was not independently verified.
Research-material market context only. Seine Bio does not sell lyophilized powders for self-reconstitution or offer this research compound. This figure does not price a finished clinical product; any lawful treatment requires its own quote. Membership does not provide the named investigational compound.
Discuss my care optionsPrice sources & what is included
Public research-material listings reviewed October 7, 2026. Prices and stock can change; taxes and shipping may be additional. These source links document laboratory listings, not patient-use products, supplier quality or lawful clinical availability.
Optional product-savings membership
Start with a personal care conversation.
$20Per month · Cancel anytime
- 2% off products; therapy services and membership dues excluded
- Free two-business-day shipping after dispatch on $100+ physical-product orders before discounts and taxes in the contiguous United States
- Cancel anytime to stop future membership renewals
Medication, labs, products and additional treatment cost extra. Care is subject to clinical fit and availability. Membership does not guarantee a prescription, named peptide or research enrollment.
Create a free account ↗Understand the topic
Thymosin Alpha-1.
A clearer overview.
Start with the research. Keep your goals in view.
Research topic in the United States. Thymosin Alpha-1 is not an FDA-approved general immune or wellness treatment. This page does not offer TA1 treatment.
What makes it interesting.
Thymosin Alpha-1, or TA1, is a 28-amino-acid peptide involved in immune biology. The synthetic version is known as thymalfasin. Research examines immune-cell signaling, but the goal is not simply to make every immune response stronger; disease, treatment and immune status all matter.
The story behind the interest.
TA1 was isolated from a thymus fraction and characterized in 1977. It has a longer clinical research history than many peptides discussed online, including studies in infectious disease and serious illness. That history needs to be read condition by condition, rather than repackaged as proof of general wellness benefit.
Evidence before expectations
Read beyond
the headline.
A useful research discussion includes the study design, the population and the outcome measured.
Read the original sourcesThe 2025 TESTS study was a multicentre, blinded, placebo-controlled phase 3 trial in patients with sepsis. It did not demonstrate a statistically significant overall 28-day mortality benefit. The article has a correction, which should be read alongside the original report.
FDA’s 2024 briefing evaluated multiple proposed conditions and identified substantial evidence and product-quality questions. Findings in a hospital population cannot establish benefit for a person seeking more energy or fewer everyday illnesses.
Clinical evidence is not all-or-nothing: a larger research record can be worth discussing without supporting every advertised use. Ask which condition, formulation, study and patient population a claim actually applies to.
| Research setting | What the record shows | What it does not establish |
|---|---|---|
| Long research history | TA1 was characterized from a thymic fraction in 1977. | A long history does not validate all wellness claims. |
| 2025 TESTS trial | A large sepsis trial did not show significant overall mortality benefit. | Does not support routine immune boosting for healthy people. |
| Condition-specific evaluation | FDA reviewed a range of proposed clinical uses in 2024. | The evidence needs to be assessed separately for each use. |
Understand the evidence
Understanding doses
and cycles.
A clear reference for your conversation with a clinician.
Research doses describe a specific study, not a treatment plan. Online popularity does not establish safety.
| Preparation / context | Dose reference | Frequency | Duration / cycle | Evidence & source |
|---|---|---|---|---|
| Thymosin Alpha-1 | Not established for this proposed wellness use | Not established | No validated human on/off cycle | Evidence limitations There is no FDA-approved U.S. immune-wellness dosing cycle. Read the source |
Swipe or scroll sideways to see every column. There is no universal peptide cycle. A published trial, a product label and an informal online protocol are different kinds of information.
Sources reviewed October 7, 2026. A dose listed here does not establish availability or suitability through Seine Bio.
Discuss my optionsAn honest view of uncertainty
Ask better questions.
Understand the concerns.
Missing safety information cannot be treated as proof that a product is safe.
Risks & concerns
What deserves attention.
- FDA’s briefing identifies immunogenicity, aggregation and product-characterization concerns.
- An immune-active compound warrants individual consideration for autoimmune disease, transplantation, immune-suppressing treatment or cancer care.
- Evidence from one disease and preparation does not establish interactions or long-term safety for general wellness use.
A compound’s name, a purity claim or research-use labeling does not establish patient-ready quality, sterility or a reliable clinical outcome.
Regulatory context
Review is not an approval.
FDA evaluated TA1 in December 2024, separately from the July 2026 group. It appears in the current withdrawn-nomination table. Foreign use or a nomination change does not make it an FDA-approved drug.
Compounding review, permission to conduct research and approval of a finished drug are different decisions. This page is an invitation to learn and discuss appropriate care, not a statement that this compound can be supplied.
Check the official sourcesThe goal behind your search
Understand your concerns.
Choose a useful next step.
Persistent illness, fatigue or concerns about immune function deserve a discussion of what has been happening and what has already been evaluated. We can explain the appropriate care pathway and referral options. Established care and specialist input may be more relevant than an experimental immune product.
Share your goal.
Create a free account. Tell the team which care conversation interests you; keep sensitive health details for private clinical intake.
Understand your options.
The appropriate clinician can discuss the research, its limitations and established alternatives. Relevant research resources may be discussed when appropriate; eligibility and access are controlled by the study or sponsor.
Choose your next step.
Review suitability, available care and clear costs before deciding. A plan may involve established treatment, a referral or further assessment. No particular prescription or research access is guaranteed.
Good questions welcome
Make the next
step clearer.
You can be curious about research and still choose a practical care path available today.
Is Thymosin Alpha-1 the same as TB-500?
No. TA1 and thymosin-beta-related peptides are distinct substances. Similar names do not make their biological effects, evidence or safety interchangeable.
Does the sepsis trial prove a general immune benefit?
No. It studied hospitalized sepsis patients and did not show a statistically significant overall mortality benefit. It cannot establish a general wellness effect in people outside that population.
Does use outside the US mean it is FDA approved?
No. Regulatory decisions are jurisdiction specific. This page does not represent TA1 as an FDA-approved medicine or as a treatment available through Seine Bio.
Can I ask about TA1 and other options?
Yes. Bring the question and the health goal behind it. A clinician can discuss the evidence and appropriate established care. An inquiry does not guarantee TA1, another prescription or research access.
A simple place to start
Bring your questions.
Explore your next step.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
- A free account with basic contact details
- Screening and clear costs before payment
- Established alternatives discussed when appropriate
An inquiry is not an application for guaranteed access to this compound. Membership does not include or guarantee experimental treatment. Any clinical care and costs will be explained separately.
Start with a free account.
Optional membership: $20/month.
Optional · $20/month · Cancel anytime. Medications, labs, products, additional therapy and separately priced treatments cost extra.
Create a free account to request review and manage purchases. Paid membership is optional. Clinical review and authorization still apply where required, and any separate service charges are shown before you agree to pay.
Please keep medical history, medications and sensitive personal details for private clinical intake.
Learn more
Read the sources.
Bring your questions.
Original research and official regulatory materials help put claims into context. Study links are educational and do not establish a treatment offer.
Reviewed October 7, 2026. Regulatory status and research records may change.
Questions about Thymosin Alpha-1?Start a care conversation
Start my inquiryClinical inquiries: age 18+. Research information does not imply treatment availability. Clinical decisions require an individual evaluation by an appropriate licensed clinician. An inquiry or membership does not guarantee a prescription, research enrollment or a specific outcome.
We do not provide emergency services. For immediate danger or a medical emergency, call 911. For a mental health crisis in the U.S., call or text 988.